Form 4: Jazz Pharma Exec Sells Shares, Exercises Options

Jazz Pharmaceuticals' SVP and Chief Accounting Officer, Patricia Carr, reported exercising stock options and selling shares, including those from an employee stock purchase plan.

Summary

• Patricia Carr, SVP, Chief Accounting Officer of Jazz Pharmaceuticals plc, reported multiple transactions on November 18, 2025.
• She sold 69 ordinary shares, which were acquired under a Section 423 Employee Stock Purchase Plan on May 30, 2025, at a price of $181.66 per share.
• She exercised non-qualified stock options to acquire 5,250 ordinary shares at an exercise price of $136.18 per share.
• Immediately following the option exercise, she sold 5,250 ordinary shares at $182.07 per share.
• The options were granted on March 2, 2017, under the Issuer's 2011 Equity Incentive Plan and were fully vested as of March 2, 2021.
• Following these transactions, Patricia Carr beneficially owns 7,012 ordinary shares directly.

Sentiment

Score: 5

Explanation: Neutral. This is a standard insider transaction filing (Form 4) reporting an executive's exercise of options and subsequent sale of shares, along with a minor sale of ESPP shares. It reflects personal financial management rather than a direct positive or negative signal about the company's operational performance or future prospects.

Positives

• The exercise of options indicates the executive realized value from previously granted equity incentives.
• The sale price of $182.07 for the exercised shares is significantly higher than the exercise price of $136.18, indicating a profitable transaction for the executive.

Negatives

• The executive sold a total of 5,319 shares (69 from ESPP and 5,250 from option exercise) on the open market, which represents a reduction in direct ownership from the pre-transaction level of 7,081 shares to 7,012 shares, and a full liquidation of the recently acquired ESPP shares and the newly exercised options.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing (Form 4) and does not provide specific industry context. It reflects an executive's personal financial planning related to their compensation.

Stakeholder Impact

• Shareholders: The sale of shares by an executive could be interpreted in various ways, but the exercise-and-sell pattern is common for liquidity and tax planning. The overall impact on share price from this volume is likely minimal.
• Employees: The exercise of stock options and participation in an ESPP are standard components of executive compensation, demonstrating the realization of value from equity incentives.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions by an executive, involving the exercise of stock options and subsequent sale of shares for liquidity and tax purposes, alongside a minor sale of shares from an employee stock purchase plan. Such transactions are common and generally do not indicate a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. The executive still retains a significant number of shares, suggesting continued alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing provides no new material information to alter a prior investment thesis.

Keywords

Jazz Pharmaceuticals, JAZZ, Form 4, Insider Trading, Stock Options, Share Sale, Executive Compensation, Patricia Carr, Employee Stock Purchase Plan